3 reports

  • Chimerix Raises USD122 Million in Public Offering of Shares

Grade ##-## (on a scale of Grade ##-##) safety laboratory changes were observed in some subjects in the first three dosing cohortsnone were considered clinically significant.

  • Antiviral
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Chimerix, Inc.

The study identified novel HIV-## CAIs with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro.

  • Antiviral
  • Hepatitis Treatment
  • HIV AIDS
  • Therapy
  • Corporate Finance

Peramivir antiviral to treat patients with influenza in Japan, on January ##, 2010.

  • Antiviral
  • Pharmaceutical
  • United States
  • Corporate Finance
  • BioCryst Pharmaceuticals, Inc.